The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line

Melanoma Research

Volumn 13, Issue 3, 2003, Pages 219-229

  Jackson, David P ^a   Watling, Diane ^b   Rogers, Neil C ^b   Banks, Rosamonde E ^a   Kerr, Ian M ^b   Selby, Peter J ^a   Patel, Poulam M ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Interferon; JAK; Melanoma; Signal transduction; STAT

Indexed keywords

INTERFERON; JANUS KINASE; PROTEIN; RIBONUCLEASE; STAT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL HETEROGENEITY; CELL LINE; CELL PROLIFERATION; CLINICAL PATHWAY; CONTROLLED STUDY; DATA ANALYSIS; ELECTROPHORETIC MOBILITY; ENZYME ASSAY; HLA SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL DIVISION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERONS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MELANOMA; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0037502779     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200306000-00001     Document Type: Article

References (44)

1. Agarwala SS, Kirkwood JM. Interferons in melanoma. Curr Opin Oncol 1996; 8:167-174.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996; 14:7-17.
3. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-2458.
4. Grob JJ, Dreno B, Delasalmoniere P, Delaunay M, Cupissol D, Guillot B, et al. Randomized trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351:1905-1910.
5. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, et al. Adjuvant interferon alpha-2a treatment in resected primary stage- II cutaneous melanoma. J Clin Oncol 1998; 16:1425-1429.
6. Ramani P, Balkwill FR. Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice. Br J Cancer 1988; 58:350-354.
7. Thomas H, Balkwill FR. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol Ther 1991; 52:307-330.
8. Czarniecki CW, Fennie CW, Powers DB, Estell DA. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. J Virol 1984; 49:490-496.
9. Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R, et al. Antitumour activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis and immunophenotype. J Invest Dermatol 1990; 95:231S-237S.
10. Jakschies D, Hochkeppel HK, Horisberger MA, Deicher H, von Wussow P. Correlation of the antiproliferative effect and the Mx-homologous protein induction by IFN in patients with malignant melanoma. J Invest Dermatol 1990; 95:238S-241S.
11. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. J Natl Cancer Inst 1992; 84:1185-1190.
12. Worm M, Schadendorf D, Czarnetzki BM. Responiveness to interferon treatment of human melanoma cells correlates to immunophenotype. Melanoma Res 1993; 3:29-33.
13. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-264.
14. Beadling C, Guschin D, Witthuhn BA, Ziemiecki A, Ihle JN, Kerr IM, et al. Activation of JAK kinases and STAT proteins by interleukin-2 and interferon alpha, but not the T cell antigen receptor, in human T lymphocytes. EMBO J 1994; 13:5605-5615.
15. Stephens JM, Lumpkin SJ, Fishman JB. Activation of signal transducers and activators of transcription 1 and 3 by leukemia inhibitory factor, oncostatin-M, and interferon-gamma in adipocytes. J Biol Chem 1998; 273:31408-31416.
16. Fasler-kan E, Pansky A, Wiederkehr M, Battegay M, Heim H. Interferon-alpha activates signal transducers and activators of transcription 5 and transcription 6 in Daudi cells. Eur J Biochem 1998; 254:514-519.
17. Meinke A, Barahmand-Pour F, Wohrl S, Stoiber D, Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol 1996; 16:6937-6944.
18. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors - studies from gene knockout mice. Cytokine Growth Factor Rev 2001; 12:133-142.
19. Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF, et al. Beta-interferon and oncostatin-m activate Raf-1 and mitogen-activated protein-kinase through a JAK1-dependent pathway. Mol Cell Biol 1997; 17:3833-3840.
20. Uddin S, Majchrzak B, Woodson J, Arunkumar P, Alsayed Y, Pine R, et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem 1999; 274:30127-30131.
21. David M, Petricoin E3, Benjamin C, Pine R, Weber MJ, Larner AC. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science 1995; 269:1721-1723.
22. Goh KC, Haque SJ, Williams BR. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J 1999; 18:5601-5608.
23. Burfoot MS, Rogers NC, Watling D, Smith JM, Pons S, Paonessaw G, et al. Janus kinase-dependent activation of insulin-receptor-substrate-1 in response to interleukin-4, oncostatin-M, and the interferons. J Biol Chem 1997; 272:24183-24190.
24. Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH. STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 1997; 276:1418-1420.
25. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 1999; 27:1583-1592.
26. Bromberg JF, Horvath CM, Wen ZL, Schreiber RD, Darnell JE. Transcriptionally active stat1 is required for the antiproliferative effects of both interferon-alpha and interferon-gamma. Proc Natl Acad Sci USA 1996; 93:7673-7678.
27. Chin YE, Kitagawa M, Su WC, You ZH, Iwamato Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF/CIP1 mediated by STAT1. Science 1996; 272:719-722.
28. Ramana CV, Stark GR. Roles of stat1 in regulating c-myc gene-expression in response to IFN-gamma. Eur Cytokine Netw 1998; 9:298.
29. Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, et al. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 1998; 47:113-120.
30. Sun WH, Jandeska S, Pabon C, Rosen ST. Interferon resistance in a cutaneous T-cell lymphoma line is associated with the loss of stat1 protein. J Invest Dermatol 1997; 108:224.
31. Yang C, Murti A, Pfeffer L. Stat3 complements defects in an interferon-resistant cell-line - evidence for an essential role for stat3 in interferon signaling and biological activities. Eur Cytokine Netw 1998; 9:196.
32. Watling D, Guschin D, Müller M, Silvennoinen O, Witthuhn BA, Quelle FW, et al. Complementation by the protein kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature 1993; 366:166-170.
33. Muller M, Laxton C, Briscoe J, Schindler C, Improta T, Darnell JEJ, et al. Complementation of a mutant cell line: central role of the 91 kDa polypeptide of ISGF3 in the interferon-alpha and -gamma signal transduction pathways. EMBO J 1993; 12:4221-4228.
34. Muller M, Briscoe J, Laxton C, Guschin D, Ziemiecki A, Silvennoinen O, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 1993; 366:129-135.
35. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995; 11:69-74.
36. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 1997; 272:28779-28785.
37. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 2000; 85:720-725.
38. Bearzatto A, Orlandi L, De MC, Daidone MG, Zaffaroni N. Lack of p21waf1 and p27kip1 protein induction by interferon-alpha2a in human melanoma cell lines. Melanoma Res 1999; 9:457-463.
39. Rani MR, Leaman DW, Han Y, Leung S, Croze E, Fish EN, et al. Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 1999; 274:32507-32511.
40. Pellegrini S, John J, Shearer M, Kerr IM, Stark GR. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway. Mol Cell Biol 1989; 9:4605-4612.
41. Uze G, Lutfalla G, Mogensen KE. Alpha and beta interferons and their receptor and their friends and relations. J Interferon Cytokine Res 1995; 15:3-26.
42. Arany I, Fleischmann CM, Tyring SK, Fleischmann WR. Interferon regulates expression of mda-6/waf1/cip1 and cyclin-dependent kinases independently from p53 in b16 murine melanoma cells. Biochem Biophys Res Commun 1997; 233:678-680.
43. Resnitzky D, Tiefenbrun N, Berissi H, Kimchi A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells. Proc Natl Acad Sci USA 1992; 89:402-406.
44. Newton Bishop JA. Molecular pathology of melanoma. Cancer Metastasis Rev 1997; 16:141-154.